Skip to main content

Table 3 PFS and OS univariate Cox regression analyses of the whole series

From: Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit

 

First-line PFS

OS

Variable

HR

95% CI

p

HR

95% CI

p

Gender

1.00

0.77–1.29

0.991

1.11

0.84–1.46

0.438

Age at diagnosis

1.02

1.01–1.03

0.001

1.04

1.02–1.05

< 0.001

Age at metastasis

1.02

1.00–1.03

0.003

1.04

1.02–1.05

< 0.001

Age at metastasis > 60 years

1.40

1.07–1.65

0.015

1.76

1.30–2.38

< 0.001

Tumor grade

1

1

  

1

  

2

1.24

0.58–2.66

0.570

0.67

0.31–1.45

0.321

3

1.37

0.63–3.00

0.426

1.04

0.47–2.28

0.921

pT

1

1

  

1

  

2

0.82

0.18–3.74

0.806

1.27

0.27–6.00

0.764

3

1.04

0.25–4.21

0.956

1.92

0.47–7.81

0.360

4

1.31

0.32–5.36

0.706

2.76

0.67–11.39

0.158

Right sided tumor versus other (left sided and rectum)

1.24

0.94–1.61

0.115

1.36

1.03–1.80

0.030

Metastasis site

Liver

1

  

1

  

Other sites

1.11

0.76–1.64

0.579

1.05

0.71–1.57

0.796

Multiple sites

1.29

0.97–1.70

0.070

1.17

0.88–1.57

0.277

Multiple site versus single site metastases

1.25

0.91.62

0.082

1.16

0.89–1.52

0.274

KRASmutant (exon 2) versus wild-type

1.25

0.97–1.61

0.083

1.32

1.01–1.72

0.039

First-line therapy

Chemotherapy plus bevacizumab

1

  

1

  

Chemotherapy plus anti-EGFR

1.03

0.49–2.13

0.933

1.05

0.45–2.41

0.909

Chemotherapy alone

1.44

1.09–1.88

0.008

0.91

0.68–1.22

0.544

First-line therapy

Chemotherapy plus bevacizumab versus other

0.71

0.54–0.93

0.012

1.09

0.81–1.45

0.568

Surgical resection of primary tumor (yes versus no)

0.59

0.40-0.88

0.009

0.64

0.42–0.96

0.030

Surgical resection of metastasis (yes versus no)

0.55

0.41–0.72

< 0.001

0.44

0.32–0.59

< 0.001

Local non-surgical treatment of metastasis (yes versus no)

0.60

0.45–0.80

< 0.001

0.47

0.35–0.64

< 0.001

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us